đŸȘ Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings


Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.


If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.


If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies


Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

Your retention will contact you in a few minutes with more information about this trading strategy.
ozios_close

{{ requiredField }}

{{ validEmail }}

{{ item.name }}
{{ item.dial_code }}

{{ validPhone }}

Your message was sent
Too many tries. Try in 2 minutes
locked content icon
This content is locked
to unlock it
return icon
Return
Return

Sanofi to cure rare diseases, buys patent for 2.2 billion

French pharmaceutical company Sanofi has agreed to buy the INBRX-101 drug development project from Inhibrx Inc. It is opening a new account for about $2.2 billion in a bid to boost its rare disease business. The acquisition is in line with the company's portfolio growth strategy and complements Sanofi's 30-year heritage in rare diseases as well as its industry leadership in immunology and inflammation.

About Sanofi

Sanofi is engaged in the research, manufacture and distribution of pharmaceutical products. It operates in the following segments: Pharmaceuticals, Healthcare and Vaccines. The Pharmaceuticals segment includes specialty care, diabetes and cardiovascular disease, established prescription and generic drugs, and research, development, and manufacturing activities. The Health Care segment includes commercial operations for proprietary products, while the Vaccines segment consists of Sanofi Pasteur's commercial operations. The company was founded in 1973 and is headquartered in Paris, France.

 

Details of the latest deal

INBRX-101, an experimental drug developed by Inhibrx Inc, is currently in the second of three phase II clinical trials. It is designed to treat alpha-1 antitrypsin deficiency (AATD), an inherited rare disease that causes progressive degeneration of lung tissue.

The boards of directors of both parties have unanimously approved the acquisition agreement, which is subject to final regulatory approval and other conditions. The acquisition is expected to be completed in the second quarter of 2024.[1] Sanofi will assume and retire Inhibrx's outstanding debt to third parties and fund Inhibrx with $200 million in cash. Sanofi will also retain an 8% interest in the newly formed New Inhibrx.

Strategy change: R&D through acquisitions

Sanofi, which gets most of its revenue from anti-inflammatory treatments, last year dropped its 2025 profit targets to boost research and development (R&D). CEO Paul Hudson's unexpected change in strategy led to a 15% drop in the share price.*

Despite dominating sales of asthma and eczema drug Dupixent, it was the company's lack of drug development activity that was criticised by investors.

In response to investors, Sanofi provided a comprehensive update to its strategy called Play to Win. This strategy continues to focus on the critical goals of implementing transformative medicine and bringing vaccines to market. It also includes promoting efficient deployment of resources and increasing R&D productivity.

As part of the new strategy, the Company aims to improve its capital structure, with the support of senior management, to support an increase in its annual free cash flow of approximately 50%. The focus is to be on the APAC region, which accounts for up to 18% of global sales.[1]

Snímek obrazovky 2024-01-24 v 15.08.41

Sanofi's share price development over the last 5 years. Source: Yahoo finance.*

History of Sanofi acquisitions

In March 2023, Sanofi bought Provention Bio Inc. for $2.9 billion to boost its U.S.-approved portfolio of type 1 diabetes treatments after setbacks with the development of its own drugs for the disease. Provention's Tzield became the first drug indicated to delay the onset of third- and final-stage type 1 diabetes in adults and children as young as 8 years old.

CEO Paul Hudson said in response to the acquisition that the company sees great promise in the development of type 1 diabetes drugs and reaffirmed its commitment to avoiding further development of drugs for type 2 diabetes and obesity.[1] The rationale is to guide the company on a path of increasing profitability, in segments where there is more potential to do so.

 

Conclusion

Despite Sanofi's dominant revenues from sales of asthma and eczema drug Dupixent, investors have criticized the company's lack of drug development activities. Thus, the company proceeded with a new strategy. This involves promoting efficient deployment of resources and increasing R&D productivity. The company has also set a target of increasing its annual free cash flow by around 50%. This enabled it to fund the acquisition of Inhibrx with $200 million in cash. 

Adam Austera, principal analyst at Ozios

* Past performance is no guarantee of future results

[1] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate or based on the current economic environment, which may change. Such statements are not guarantees of future results. They involve risks and other uncertainties that are difficult to predict. Results may differ materially from those expressed or implied by any forward-looking statements.


[1] https://www.citibank.com/tts/case-studies/sanofi-capital-goals.html

[2] https://www.fiercepharma.com/pharma/sanofi-throws-down-29b-acquire-diabetes-partner-provention

Disclaimer:

The material herein is considered as marketing communication under the relevant laws and regulations, and as such is not a subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and should not be construed as containing investment advice, or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. The published content is intended for educational/informational purposes only. It does not take into account readers’ financial situation, personal experience or investment objectives. APME FX Trading Europe Ltd makes no representation that the information provided is accurate, current or complete; and therefore, assumes no liability for any losses arising from investments based on the supplied content. The past performance is not a guarantee of future results.

ASML: An inconspicuous but important Dutch company experiences its historic growth

French pharmaceutical company Sanofi has agreed to buy the INBRX-101 drug development project from Inhibrx Inc. It is opening a new account for about $2.2 billion in a bid to...

MiCA: A new era of cryptocurrencies in Europe

French pharmaceutical company Sanofi has agreed to buy the INBRX-101 drug development project from Inhibrx Inc. It is opening a new account for about $2.2 billion in a bid to...

Samsung has traded Google for its competition. Galaxy S24 will have Baidu's AI under the casing

French pharmaceutical company Sanofi has agreed to buy the INBRX-101 drug development project from Inhibrx Inc. It is opening a new account for about $2.2 billion in a bid to...
We are also available at +357 25 054 734 online icon
© 2024 APME FX TRADING EUROPE LTD

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 86,61% of retail investor' accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Read our Risk Disclosures.